BioMed Research International / 2014 / Article / Tab 3

Research Article

Effects of Anti-TNF Alpha Drugs on Disability in Patients with Rheumatoid Arthritis: Long-Term Real-Life Data from the Lorhen Registry

Table 3

Patients stratified by their clinical and demographic characteristics. The table shows the number of patients in each subgroup and their mean HAQ scores (except in the case of missing data). The bold indicate that the difference between the subgroups is statistically significant ( ).

Baseline6th month12th month18th month24th month30th month36th month42th month48th month54th month60th month

GenderF; M847-186847-186741-163660-145603-136413-82529-112374-81401-78303-62281-63
HAQ1.47-1.211.06-0.750-0.96-0.590.91-0.560.87-0.540.8-0.550.82-0.50.8-0.440.81-0.420.73-0.430.76-0.41

Age<65; 65; missing706-245-82706-245-82617-218-69554-193-58518-172-49375-106-14463-142-36344-97-14362-107-10269-84-12260-76-8
HAQ1.39-1.620.94-1.210.81-1.160.75-1.150.72-1.090.68-1.050.68-1.080.64-1.040.67-1.010.59-0.960.61-0.98

RFneg; <3x; 3x; missing75-110-483-36575-110-483-36563-104-416-32155-95-371-28452-91-327-26932-57-181-22547-84-276-23434-51-165-20529-56-198-19624-43-138-16022-39-139-144
HAQ1.19-1.2-1.310.82-0.89-0.960.76-0.75-0.880.71-0.73-0.840.7-0.7-0.820.55-0.62-0.750.62-0.68-0.790.62-0.56-0.760.58-0.56-0.780.56-0.49-0.720.64-0.54-0.71

Disease duration (years)<3; 3-5;5-10; 10-15; 15412-105-181-140-179-16412-105-181-140-179-16367-94-150-122-158-13331-77-131-114-139-13294-69-120-105-138-13190-50-88-69-89-9249-62-108-94-115-13170-45-76-69-85-10175-44-81-74-96-9140-30-59-54-73-9128-28-52-55-74-7
HAQ1.23-1.36-1.44-1.64-1.740.96-0.8-0.86-1.12-1.30.8-0.75-0.76-1-1.240.75-0.72-0.68-1-1.210.69-0.69-0.72-0.89-1.130.63-0.68-0.67-0.85-1.110.64-0.67-0.67-0.9-1.080.65-0.65-0.59-0.78-1.030.62-0.71-0.66-0.86-0.990.6-0.68-0.62-0.7-0.860.56-0.61-0.58-0.83-0.93

Comorbidity1; 2; 3; 4; missing380-188-86-50-329380-188-86-50-329335-163-78-45-283305-146-67-41-246284-128-62-38-227190-92-42-30-141249-114-50-34-194166-94-39-29-127177-98-44-27-133131-80-34-20-100129-73-32-20-90
HAQ1.42-1.53-1.64-1.681-1.14-1.28-1.080.84-1.04-1.2-1.180.81-0.95-1.16-1.190.8-0.85-1.16-1.010.7-0.86-1.24-1.230.76-0.83-1-0.990.69-0.76-1.21-1.080.77-0.75-1.07-1.110.66-0.7-0.92-1.20.65-0.84-0.86-1.14

Baseline HAQ score<0.5; 0.5-1; 1-2; 2; missing53-161-599-205-1553-161-599-205-1546-139-532-174-1340-118-490-143-1438-108-444-135-1423-65-310-88-934-86-389-118-1425-50-293-77-1025-58-286-98-1221-40-231-64-921-37-208-69-9
HAQ0.48-0.79-1.37-2.350.3-0.56-0.99-1.610.31-0.5-0.85-1.520.25-0.5-0.81-1.440.29-0.47-0.77-1.350.14-0.46-0.71-1.330.15-0.5-0.71-1.320.14-0.47-0.71-1.170.15-0.43-0.69-1.230.14-0.51-0.64-1.10.14-0.43-0.63-1.15

Baseline DAS28<3.2; 3.2-5.1; 5.1; missing30-218-773-1230-218-773-1229-194-671-1026-161-607-1121-160-547-1111-105-370-918-135-477-1112-98-335-1017-99-354-913-73-272-715-65-258-6
HAQ1.01-1.12-1.540.55-0.78-1.10.59-0.69-0.970.72-0.63-0.920.33-0.63-0.880.31-0.55-0.840.27-0.57-0.840.38-0.56-0.80.39-0.64-0.80.37-0.52-0.740.35-0.61-0.74

Anti-TNF drugADA; ETA; INF; missing301-227-494-11301-227-494-11260-193-442-9220-171-404-10208-153-368-10159-97-231-8183-128-320-10143-84-219-9133-84-254-8102-68-188-780-57-201-6
HAQ1.24-1.37-1.570.86-0.99-1.10.77-0.89-0.970.76-0.88-0.890.7-0.87-0.840.73-0.84-0.750.7-0.86-0.770.67-0.86-0.720.65-0.92-0.740.67-0.74-0.660.72-0.71-0.67

SteroidsNo; yes166-867166-867148-756132-673124-61587-408107-53483-37285-39468-29765-279
HAQ1.29-1.450.88-1.030.74-0.920.72-0.870.68-0.830.65-0.780.65-0.790.67-0.750.65-0.770.64-0.690.61-0.71

DMARDsNo; yes83-95083-95068-83653-75251-68838-45748-59336-41938-44129-33625-319
HAQ1.53-1.421.05-10.97-0.890.91-0.840.9-0.81.11-0.730.85-0.760.89-0.720.97-0.730.9-0.661-0.67

F: female; M: male; RF: rheumatoid factor; <3x RF: low titre [<3 times the upper normal limit of 42 IU/mL]; HAQ: Health Assessment Questionnaire; DAS28: disease activity score in 28 joints; TNF: tumour necrosis factor; ADA: adalimumab; ETA: etanercept; INFL: infliximab; DMARDs: disease modifying antirheumatic drugs.